跳到正文
原文
Medical Xpress·· 2026-10-07精选AI 评分76

炎症性关节炎患者接种新冠补充疫苗时暂停 DMARD 不增强抗体反应,复发风险显著升高

Pausing certain arthritis drugs after COVID-19 vaccination raises flare risk without improving antibody response

AI 导读

随机对照试验显示,840 例炎症性关节炎患者接种新冠疫苗补充剂量时暂停 DMARD 两周不增强抗体反应,而疾病复发风险显著升高(OR 2.27)。该研究发表于 JAMA Internal Medicine,暂停治疗者复发风险在 JAKi 使用者中最明显;作者认为结果不支持为优化新冠疫苗效果而常规临时中断治疗。

推荐理由

840 例炎症性关节炎患者的随机对照试验显示,接种补充新冠疫苗时暂停 DMARD 不增强抗体反应,反而增加复发风险。

正文 · 原文
Holding DMARDs at time of COVID-19 vaccination not warranted in those with inflammatory arthritis

For patients with inflammatory arthritis, holding certain disease-modifying antirheumatic drugs (DMARDs), namely select biologic or Janus kinase inhibitor (JAKi) therapies, for two weeks at the time of a supplemental COVID-19 vaccine dose does not enhance humoral immunogenicity, according to a study published online Oct. 5 in JAMA Internal Medicine.

Jeffrey R. Curtis, M.D., M.P.H., of the University of Alabama at Birmingham and colleagues randomly assigned 840 patients with inflammatory arthritis to continue or hold therapy for two weeks following administration of their next supplemental COVID-19 vaccine dose. The patients had received a primary mRNA COVID-19 vaccine series and were receiving anti-tumor necrosis factor medications, anti-interleukin-17 inhibitors, abatacept or JAKi.

The researchers found that from baseline to the postdose visit, there were substantial increases in severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G antibody levels across all groups. The geometric mean fold rise ratio (hold/continue) was 0.96 (95% confidence interval, 0.36 to 2.56) in the primary intention-to-treat analysis, indicating no significant between-arm difference in humoral immunogenicity. Across drug subgroups and drug half-life categories, the results were consistent.

Disease flare risk was significantly increased with holding therapy (odds ratio, 2.27; 95% confidence interval, 1.41 to 3.65), which was most pronounced among those who used JAKi therapies. Comparable adverse events were seen between medication arms and occurred more frequently in the hold group.

"Given the increased flare risk and absence of humoral immunogenicity benefit, these findings do not support routine temporary interruption for COVID-19 vaccine optimization," the authors write.

Publication details

Jeffrey R. Curtis et al, Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis, JAMA Internal Medicine (2026). DOI: 10.1001/jamainternmed.2026.4894

Journal information: JAMA Internal Medicine

Key medical concepts

Arthritis

Who's behind this story?

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Copyright © 2026 HealthDay. All rights reserved.

Citation: Pausing certain arthritis drugs after COVID-19 vaccination raises flare risk without improving antibody response (2026, October 6) retrieved 6 October 2026 from https://medicalxpress.com/news/2026-10-arthritis-drugs-covid-vaccination-flare.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com